🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

US FDA approves GE HealthCare's diagnostic drug for heart disease

Published 09/27/2024, 06:14 PM
Updated 09/27/2024, 06:15 PM
© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo
GEHC
-

(Reuters) - The U.S. Food and Drug Administration approved GE HealthCare (NASDAQ:GEHC)'s diagnostic drug for use in detection of coronary artery disease, the company said on Friday.

Flyrcado, which is a radioactive diagnostic drug for positron emission tomography (PET) myocardial perfusion imaging (MPI), will be available in some U.S. markets in early 2025 before being expanded.

PET-MPI is a non-invasive imaging test which uses a type of nuclear medicine called radioactive tracers to asses how well blood flows to the muscle of the heart. The 3D images of the tracer's distribution can then be produced.

The company said Flyrcado, which can be manufactured in an offsite pharmacy and delivered as a ready-to-use unit dose, has the potential to expand access to PET-MPI, including improving diagnostic accuracy in difficult-to-image patients such as those with a high body mass index and women.

Doctors have underscored Flyrcado's distinct clinical benefits such as higher-quality imaging, greater defect resolution and improved workflow, brokerage Stifel said in a note ahead of the approval.

Use of Flyrcado helped accurately classify 74% to 89% of participant scans in a study.

GE HealthCare said Flyrcado delivers higher diagnostic efficacy in patients with known or suspected CAD, compared to SPECT MPI which is the predominant procedure currently being used.

CAD is the narrowing or blockage of the coronary arteries, which supply oxygen-rich blood to the heart. It impacts over 18 million adults in the U.S., and is the leading cause of death in the country, according to the FDA.

Flyrcado decays ten times slower than currently approved cardiac PET radiotracers, GE HealthCare said, which can help combine exercise stress testing with imaging.

© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo

The company also has similar products for detection of breast cancer and Alzheimer's disease.

Stifel analysts estimate approval of Flyrcado could add about 0.3% to 0.6% of sales growth for the company in the medium to long term.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.